BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to SUM159 cell line is 175
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| KDM1A | 29079 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0021 | 33057995 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Paclitaxel | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.0891 | 35401817 |
| KLF4 | 6348 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs and RT-PCR | NA | 0.48 | 0.0891 | 29249663 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | Western Blotting and RT-PCR followed by SFA | NA | 0.48 | 0.1304 | 28951456 |
| MYC | 7553 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Lithium Chloride | Western Blotting and SFA | NA | 0.48 | 0.1304 | 29356693 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Paclitaxel | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5461 | 35401817 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA and Western Blotting | NA | 0.48 | 0.5461 | 33530373 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 29243835 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.5461 | 29356693 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Lithium Chloride | Western Blotting and SFA | NA | 0.48 | 0.5461 | 29356693 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Purmorphamine | Western Blotting and SFA | NA | 0.48 | 0.5461 | 29356693 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA and qRT-PCR | NA | 0.48 | 0.5461 | 35064101 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | qRT-PCR and SFA | NA | 0.48 | 0.5461 | 31850822 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA and qRT-PCR | NA | 0.48 | 0.5461 | 28991374 |
| NANOG | 20857 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.5461 | 31337967 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Paclitaxel | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.6448 | 35401817 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs and RT-PCR | NA | 0.48 | 0.6448 | 29249663 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA and Western Blotting | NA | 0.48 | 0.6448 | 33530373 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 29243835 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.48 | 0.6448 | 29356693 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA and qRT-PCR | NA | 0.48 | 0.6448 | 35064101 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | qRT-PCR and SFA | NA | 0.48 | 0.6448 | 31850822 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA and qRT-PCR | NA | 0.48 | 0.6448 | 28991374 |
| POU5F1 | 9221 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by qRT-PCR | NA | 0.48 | 0.6448 | 31337967 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Paclitaxel | SFA followed by qRT-PCR and Western Blotting | NA | 0.48 | 0.5695 | 35401817 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs and RT-PCR | NA | 0.48 | 0.5695 | 29249663 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA and qRT-PCR | NA | 0.48 | 0.5695 | 35064101 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | qRT-PCR and SFA | NA | 0.48 | 0.5695 | 31850822 |
| SOX2 | 11195 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA and qRT-PCR | NA | 0.48 | 0.5695 | 28991374 |
| TGFB1 | 11766 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | qPCR followed by Western Blotting and SFA | NA | 0.48 | 0.0138 | 28054666 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | Western Blotting and SFA followed by ALDEFLUOR assay | NA | 0.4 | 0.684 | 33797754 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | ALDEFLUOR assay followed by RT-PCR and SFA | NA | 0.4 | 0.684 | 31850822 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.684 | 29243835 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.4 | 0.684 | 29356693 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | ALDEFLUOR assay followed by SFA | NA | 0.4 | 0.684 | 35064101 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | ALDEFLUOR assay followed by SFA | NA | 0.4 | 0.684 | 35110528 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | ALDEFLUOR assay followed by SFA | NA | 0.4 | 0.684 | 35512572 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Paclitaxel | SFA and ALDEFLUOR assay | NA | 0.4 | 0.684 | 35401817 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by ALDEFLUOR assay | NA | 0.4 | 0.684 | 33057995 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.4 | 0.684 | 35357654 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | ALDEFLUOR assay followed by SFA | NA | 0.4 | 0.684 | 19190339 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Docetaxel | ALDEFLUOR assay and SFA | NA | 0.4 | 0.684 | 29921732 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | ALDEFLUOR assay followed by SFA | NA | 0.4 | 0.684 | 29620216 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | ALDEFLUOR assay followed by SFA | NA | 0.4 | 0.684 | 30344009 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | ALDEFLUOR assay followed by SFA | NA | 0.4 | 0.684 | 30460610 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | ALDEFLUOR assay followed by SFA | NA | 0.4 | 0.684 | 31619923 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by ALDEFLUOR assay | NA | 0.4 | 0.684 | 28054666 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Docetaxel | SFA followed by ALDEFLUOR assay | NA | 0.4 | 0.684 | 28978427 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Doxorubicin | SFA followed by ALDEFLUOR assay | NA | 0.4 | 0.684 | 28978427 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Paclitaxel | SFA followed by ALDEFLUOR assay | NA | 0.4 | 0.684 | 28978427 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Paclitaxel | SFA followed by ALDEFLUOR assay | NA | 0.4 | 0.684 | 30482914 |
| ALDH1A1 | 402 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by ALDEFLUOR assay | NA | 0.4 | 0.684 | 31337967 |
| PROM1 | 9454 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | Western Blotting and SFA followed by FACs | NA | 0.4 | 0.7582 | 33797754 |
| SOX9 | 11204 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs and RT-PCR | NA | 0.32 | 0.0244 | 29249663 |
| TWIST1 | 12428 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs and RT-PCR | NA | 0.32 | 0.0191 | 29249663 |
| ADORA2B | 264 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0042 | 35401817 |
| BOP1 | 15519 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | Western Blotting and SFA | NA | 0.28 | 0.0021 | 33797754 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.456 | 30262865 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs | NA | 0.28 | 0.456 | 31729259 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Docetaxel | FACs and SFA | NA | 0.28 | 0.456 | 29921732 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs followed by CFA | NA | 0.28 | 0.456 | 18366788 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs followed by SFA | NA | 0.28 | 0.456 | 29249663 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs followed by SFA | NA | 0.28 | 0.456 | 30460610 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 0.456 | 28054666 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 0.456 | 28951456 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 0.456 | 28978427 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 0.456 | 28991374 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 0.456 | 29358169 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Paclitaxel | SFA followed by FACs | NA | 0.28 | 0.456 | 30482914 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.28 | 1 | 29243835 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.28 | 1 | 29356693 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.28 | 1 | 30262865 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Lithium Chloride | Western Blotting and SFA | NA | 0.28 | 1 | 29356693 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Purmorphamine | Western Blotting and SFA | NA | 0.28 | 1 | 29356693 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs followed by SFA | NA | 0.28 | 1 | 35512572 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 1 | 35357654 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 1 | 35526049 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs | NA | 0.28 | 1 | 31729259 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Docetaxel | FACs and SFA | NA | 0.28 | 1 | 29921732 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs followed by CFA | NA | 0.28 | 1 | 18366788 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs followed by SFA | NA | 0.28 | 1 | 29249663 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs followed by SFA | NA | 0.28 | 1 | 30460610 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 1 | 28054666 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 1 | 28951456 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 1 | 28978427 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 1 | 28991374 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.28 | 1 | 29358169 |
| CD44 | 1681 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Paclitaxel | SFA followed by FACs | NA | 0.28 | 1 | 30482914 |
| CTNNB1 | 2514 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Lithium Chloride | Western Blotting and SFA | NA | 0.28 | 0.0647 | 29356693 |
| DUSP9 | 3076 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 29880481 |
| JAK2 | 6192 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | Western Blotting and SFA | NA | 0.28 | 0.0053 | 31850822 |
| JPT2 | 14137 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by Western Blotting | NA | 0.28 | 0.0021 | 29249663 |
| STAT3 | 11364 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | Western Blotting and SFA | NA | 0.28 | 0.0223 | 31850822 |
| CXCR1 | 6026 | HTM/LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0032 | 19190339 |
| FBXO21 | 13592 | HTM/LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 19190339 |
| IL8 | 6025 | HTM/LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0159 | 19190339 |
| NFYA | 7804 | HTM/LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 19190339 |
| NOTCH2 | 7882 | HTM/LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0117 | 19190339 |
| RAD51L11 | NA | HTM/LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics and qRT-PCR | Up | 0.24 | 0.0011 | 19190339 |
| ALDH1A3 | 409 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | RT-PCR followed by SFA | NA | 0.2 | 0.0201 | 31850822 |
| ALDH1A3 | 409 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Paclitaxel | SFA followed by FACs | NA | 0.2 | 0.0201 | 30482914 |
| B4GALNT1 | 4117 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | qRT-PCR | NA | 0.2 | 0.0042 | 33722905 |
| BCL6 | 1001 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0032 | 35357654 |
| BMI1 | 1066 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.1135 | 31337967 |
| CXCR3 | 4540 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | qRT-PCR | NA | 0.2 | 0.0011 | 31619923 |
| SRC | 11283 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0032 | 33530373 |
| CCR5 | 1606 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs and Tumorigenicity assay | NA | 0.12 | 0.0011 | 29358169 |
| CD24 | 1645 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.12 | 0.456 | 35526049 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | Docetaxel | FACs and SFA | NA | 0.12 | 0.211 | 29921732 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs followed by CFA | NA | 0.12 | 0.211 | 18366788 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.12 | 0.211 | 28951456 |
| EPCAM | 11529 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | SFA followed by FACs | NA | 0.12 | 0.211 | 29358169 |
| ITGA6 | 6142 | LTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs followed by SFA | NA | 0.12 | 0.0265 | 35512572 |
| ALG5 | 20266 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| ARID1B | 18040 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| ASTE1 | 25021 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| ATP5MF | 848 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| CAMK2B | 1461 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| CCDC138 | 26531 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| CCNL1 | 20569 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| CD300LB | 30811 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| CHCHD8 | 24604 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| CHURC1 | 20099 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| CLIC5 | 13517 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| CMC1 | 28783 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| COL11A2 | 2187 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| COMMD6 | 24015 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| DC2 | 24448 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| DCTPP1 | 28777 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| DMACs2L | 18799 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| DNAJC19 | 30528 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| EIF3S9 | 3280 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| EPPK1 | 15577 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0042 | 19190339 |
| FAM49B | 25216 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| FBXL18 | 21874 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| GART | 4163 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 19190339 |
| GIPC3 | 18183 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| IMMP1L | 26317 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| ISCA1 | 28660 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| KLK3 | 6364 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| LSM3 | 17874 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| MRPL41 | 14492 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| MRPL42 | 14493 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| MRPL47 | 16652 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| MRPL54 | 16685 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| MRPS23 | 14509 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| NACA | 7629 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| NDUFA2 | 7685 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| NUP37 | 29929 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| PCNX1 | 19740 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| PDCD10 | 8761 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| PDCD5 | 8764 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| PNPLA2 | 30802 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| PRPF39 | 20314 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| PRPF4B | 17346 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| PSORS1C2 | 17199 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| RAD51B | 9822 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| RBIS | 32235 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| RBM15 | 14959 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| RMDN1 | 24285 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| RNF7 | 10070 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| SLC38A2 | 13448 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| SNORD50A | 10200 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| SRSF7 | 10789 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| ST3GAL3 | 10866 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| TAS2R14 | 14920 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 19190339 |
| TMEM141 | 28211 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 19190339 |
| TPRXL | 32178 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| TYW5 | 26754 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| UBL5 | 13736 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| UGGT1 | 15663 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |
| USP15 | 12613 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| WDR53 | 28786 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 19190339 |
| WWOX | 12799 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 19190339 |
| ZFP41 | 26786 | HTM | Triple Negative Breast Cancer | Carcinoma | SUM159 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 19190339 |